New Delhi, Feb 27 : India’s pharmaceutical industry has witnessed a sharp drop of 11 per cent in regulatory violation instances in 2024, according to a report. The regulatory violation instances which entail Official Action Indicated (OAI) tag by the US drug regulator, stood at 23 per cent in 2014. The drop suggests that the…


